Apollomics Inc (APLM)

Currency in USD
17.8500
+0.3600(+2.06%)
Closed·
17.85000.0000(0.00%)
·
APLM is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
17.265617.8500
52 wk Range
3.659042.1200
Key Statistics
Prev. Close
16.9
Open
17.32
Day's Range
17.2656-17.85
52 wk Range
3.659-42.12
Volume
4.35K
Average Volume (3m)
24.19K
1-Year Change
214.5375%
Book Value / Share
-1.49
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
APLM Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Analysts do not anticipate the company will be profitable this year

Apollomics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Buy

Earnings

Latest Release
24-04-2026
EPS / Forecast
0.89 / --
Revenue / Forecast
342K / --
EPS Revisions
Last 90 days

APLM Income Statement

Compare APLM to Peers and Sector

Metrics to compare
APLM
Peers
Sector
Relationship
P/E Ratio
−3.6x−4.0x−0.4x
PEG Ratio
−0.04−0.110.00
Price/Book
−12.3x2.5x2.6x
Price / LTM Sales
4.4x9.2x3.1x
Upside (Analyst Target)
-328.6%48.5%
Fair Value Upside
Unlock12.8%5.8%Unlock

Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company’s products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer and other solid tumors with MET dysregulation; and APL-102, an oral active, small molecule multiple tyrosine kinase inhibitor, which is in a in a Phase 1 clinical trial for cancer treatment. It also develops immuno-oncology products, such as APL-501, an anti-PD-1 antibody product candidate, which is in phase 1 clinical trial for the treatment of advanced or relapsed/refractory solid tumors; APL-502, an anti-PD-L1 antibody product candidate for the treatment of tumors; APL-810, a novel, rationally designed, ACCI recombinant vaccine for the treatment of gastrin immunogen; and APL-801, a CD40 and PD-L1 antibody product candidate for the treatment of tumors. The company was founded in 2015 and is based in Foster City, California.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
727.000.03%12.29K
Other Institutional Investors
101.40K4.62%1.71M
Public Companies & Retail Investors
2.09M95.35%35.39M
Total
2.2M100.00%37.11M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Maxpro Investment Co., Ltd.4.61%1,01,2481,711
FMR LLC0.03%72712

FAQ

What Is the Apollomics (APLM) Share Price Today?

The Apollomics share price today is 17.8500.

What is the current Apollomics (APLM) share price and day range?

As of 10-08-2026, the Apollomics share price is 17.8500, with a previous close of 16.9000. The share price has ranged from 17.2656 to 17.8500 today, while the 52-week range spans from 3.6590 to 42.1200.

What Is the Apollomics Market Cap?

As of today, Apollomics market cap is 37.1100M.

What Is Apollomics's Earnings Per Share (TTM)?

The Apollomics EPS (TTM) is -7.5650.

From a Technical Analysis Perspective, Is APLM a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

What Stock Exchange Does Apollomics Trade On?

Apollomics is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Apollomics?

The stock symbol for Apollomics is "APLM."

How Many Times Has Apollomics Stock Split?

Apollomics has split 1 times.

How Many Employees Does Apollomics Have?

Apollomics has 14 employees.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.